Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORMD-0801 Phase 3 Trial in Type 2 Diabetes Mellitus
2021-004226-30Phase 3Terminated
- Sponsor
- Oramed Pharmaceuticals Inc.
- Start
- Jan 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing ORMD-0801 with Placebo (2 arms). Primary endpoint: Change from baseline in HbA1c at 26 weeks. Started Jan 2022; status: terminated.
02
Drugs
ORMD-0801
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2021-004226-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004226-30.